Por: MarketWatch Business July 22, 2023
Both drugs use antibodies that attack amyloid plaque found in the brains of Alzheimer’s victims. They are the first shown to slow early-stage cognitive decline. While only a subset of the more than six million Americans with Alzheimer’s will be eligible for treatment, analysts expect sales of Lilly’s donanemab to hit $3.9 billion in 2027. Lilly stock, already lifted by its obesity drugs, trades at 42 times next 12-month earnings. There’s... + full article
The Boston Globe USA Business July 17, 2023
The race to bring Alzheimer’s drugs to patients heated up Monday when Eli Lilly released promising new clinical findings for a treatment that with one developed by Cambridge-based Biogen and its Japanese business partner that won full US approval this month.Lilly, the pharma... + más
Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity | Forbes
Biogen to cut about 1,000 jobs as it prepares for rollout of Alzheimer’s drug | The Boston Globe
The Boston Globe USA Business June 13, 2023
This is an excerpt of an article from STAT, the health and medicine news site that’s a partner to the Globe. For a full version of this story and related coverage, .Biogen, a biotech giant plagued by years of boardroom strife, said late Monday that the longtime and polarizing... + más
Biogen to pay $900M to settle allegations of improper physician kickbacks | Fox Business
Fox Business USA Business December 30, 2022
Check out what's clicking on FoxBusiness.com A report by two House committees questioned the approval process for an Alzheimer’s drug produced by Biogen. Congressional investigators called the process rife with irregularities.The drug in question is Aduhelm, which was... + más
Forbes USA Business October 15, 2022
Getty Images Key Takeaways You may have heard the overwhelmingly positive news for Biogen lately—this stock has been a rare winner during a time of extreme volatility in the stock market due to consistent rate hikes. Biogen Inc. (BIBB) is one of the older global biotech... + más
Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs | CNBC
Fox Business USA Business September 28, 2022
Dr. Stephen O'Brien, chief medical officer of Mediflix, shares how his streaming platform is trailblazing access to medical information for everyone. Shares of Biogen surged Wednesday's following news that its drug lecanemab showed promising signs of potentially... + más
Biogen shares rally as Alzheimer's drug results show promise | CBS News
Alzheimer's drug shows promise in early results of study | WPLG Local 10
CBS News USA Health September 28, 2022
Shares of Biogen and Japanese pharmaceutical company Eisai jumped Wednesday after the drug makers said their potential treatment for Alzheimer's showed promise in slowing the fatal disease that afflicts more than 6 million Americans. The companies late Tuesday results... + más
Biogen shares soar on Alzheimer's drug developments | Fox Business
Fox Business USA Business September 27, 2022
Aflac Chairman and CEO Dan Amos says record-high inflation poses a ‘challenging environment’ for consumers. Biogen has to settle allegations that it paid kickbacks to persuade doctors to prescribe its multiple sclerosis drugs. The settlement comes after former Biogen... + más
Biogen to pay $900m to settle whistle-blower suit over kickbacks | The Boston Globe
About iurex | Privacy Policy | Disclaimer |